Valuation
- Market cap
- 398,394,000
- Revenue TTM
- $0
- Net income TTM
- $-20,850,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 287,400
- Avg volume
- 1,113,902
- Day's range
- $2.86 – $3.22
- Shares out
- 133,242,000
- Stochastic %K
- 90%
- Beta
- 0.97
- Analysts
- Strong Buy
- Price target
- $10.00
Company profile
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency...
Show more
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 646 427 2727
- Website
- https://indaptusrx.com
- Address
- Three Columbus Circle, 15th Floor, New York, United States
Latest news
No headlines yet.
Stocktwits
focafoca99
Oct 20, 8:53 PM
$INDP finished its private placement, issuing 20.3M shares for about
$24M in gross proceeds.
0 replies
StockConsultant
Oct 5, 7:41 PM
Before the close, Longs at support
Great follow through buying this afternoon on the SPY and QQQ indexes.
Did a quick screen for some good long setups at support:
$CYPH $FIVN $GRPN $INDP and
$OMER stocks at https://www.stockconsultant.com
Tip diversifcation:
Capital is allocated across 8 to 12 positions, with no sector/industry representing more than two active trades.
Trading_Edge
Oct 3, 8:20 PM
$INDP — INDP continues to be one of the wildest smaller healthcare names after gaining roughly 249% during September.
The company raised around
$24M and is exploring early research around a sleep-related device following the Decoy20 reset.
That makes this less about the old pipeline and more about what management decides to do with its newly raised capital. Definitely a speculative one, but the strategic pivot has kept retail attention elevated
0 replies
Trading_Edge
Oct 2, 6:46 PM
$INDP — INDP has basically become a corporate-reset story.
After discontinuing Decoy20 enrollment, the company raised roughly
$24M and began exploring a new sleep/neurotechnology direction.
With fresh capital and a completely different potential strategy, the important question now is what management actually decides to build or acquire. 👀
0 replies
